



## Better Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 13, 2022

May 5, 2022

SAN FRANCISCO--(BUSINESS WIRE)--May 5, 2022-- [Better Therapeutics, Inc.](#) (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its first quarter 2022 financial results before the market opens on Friday, May 13, 2022. Management will host a conference call and webcast to provide a business update at 8:30 a.m. Eastern Time on Friday, May 13, 2022.

The conference call may be accessed by dialing (833) 945-2463 (domestic) or (678) 825-8211 (international) and referring to conference ID: 9776049. The live webcast may be accessed by visiting the event link at: <https://edge.media-server.com/mmc/p/xqrp5by>. Following the webcast, a replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: [investors.bettertx.com](https://investors.bettertx.com).

### About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics' PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: [bettertx.com](https://bettertx.com)

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220505006042/en/): <https://www.businesswire.com/news/home/20220505006042/en/>

### Investor Relations:

Mark Heinen

[IR@bettertx.com](mailto:IR@bettertx.com)

### Media:

Ryan McKenna at Real Chemistry

[rmckenna@realchemistry.com](mailto:rmckenna@realchemistry.com)

Source: Better Therapeutics, Inc.